+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enzalutamide Tablets Market - Global Forecast 2026-2032- Product Image
Enzalutamide Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Enzalutamide Tablets Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118173
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Enzalutamide Tablets Market is projected to reach USD 3.88 Billion in 2026. It is expected to continue growing at a CAGR of 5.10%, reaching USD 5.28 Billion by 2032.

Enzalutamide Tablets: Executive Summary and Market Context

Enzalutamide tablets are an androgen-receptor signaling inhibitor used in the management of certain advanced prostate cancers, including metastatic castration-resistant and metastatic castration-sensitive disease, subject to local regulatory approvals and clinical guidance. Market development is shaped by treatment-line positioning, prescribing pathways, safety monitoring, reimbursement access, oral-oncology infrastructure, and the evolving evidence base for combination and earlier-line use.

Treatment Pathways Are Shifting Toward Earlier and More Coordinated Use

The landscape is being transformed by earlier integration of androgen-receptor pathway inhibitors into prostate-cancer treatment algorithms, greater emphasis on multidisciplinary care, and improved stratification by disease state, prior therapy, comorbidities, and patient preference. Oral administration can support outpatient treatment, but adherence, drug interactions, fatigue, falls, hypertension, and other clinically relevant risks require structured follow-up. Diagnostic advances and more consistent guideline adoption are also increasing the importance of coordinated urology, oncology, radiology, pathology, and primary-care workflows.

Artificial Intelligence Strengthens Selection, Monitoring, and Evidence Generation

Artificial intelligence can contribute across the enzalutamide tablet pathway by assisting imaging interpretation, identifying clinically relevant patterns in electronic records, supporting trial recruitment, and improving adherence-risk identification. Predictive tools may help clinicians prioritize monitoring for toxicity or disease progression, while natural-language systems can organize longitudinal records and summarize evidence. These applications remain dependent on representative data, transparent validation, clinician oversight, privacy safeguards, and prospective evaluation; AI should complement rather than replace individualized treatment decisions.

Regional Insights: Access and Care Models Differ Across Six Major Regions

North America generally benefits from mature oncology networks, established oral-therapy pathways, and broad clinical-trial activity, while access remains influenced by payer policies and affordability. Europe combines strong guideline infrastructure with country-level differences in health-technology assessment, reimbursement, and treatment sequencing. Asia-Pacific presents diverse regulatory systems, rapidly developing oncology capacity, and substantial variation between advanced urban centers and less-served areas. Latin America is shaped by uneven diagnostic access, public-private healthcare differences, and procurement constraints. The Middle East shows concentrated specialist capacity alongside variable national coverage, while Africa faces pronounced disparities in diagnosis, oncology infrastructure, medicine availability, and continuity of care.

Group Insights: Multilateral and Economic Blocs Shape Adoption Conditions

ASEAN markets reflect varied regulatory maturity, healthcare financing, and specialist availability, making regional coordination and local access strategies important. BRICS members combine large and diverse patient populations with differing reimbursement structures, domestic manufacturing capabilities, and clinical infrastructure. The European Union benefits from shared scientific and regulatory frameworks but retains national differences in pricing, reimbursement, and implementation. G7 countries generally have advanced oncology services and evidence-generation capacity, while affordability and treatment equity remain priorities. GCC systems often feature centralized procurement and well-resourced specialist centers. NATO members span diverse health systems, so alliance membership does not eliminate country-level differences in access or clinical practice.

Country Insights: National Regulation and Care Capacity Remain Decisive

Australia and Canada pair sophisticated oncology services with geographically uneven access and public reimbursement considerations. Brazil, Mexico, India, China, and Russia show substantial internal variation in coverage, diagnostic pathways, procurement, and availability of specialist care. France, Germany, Italy, Spain, and the United Kingdom operate within strong clinical and regulatory environments, but differ in health-technology assessment, prescribing pathways, and regional implementation. Japan and South Korea have advanced oncology capabilities, with local regulatory, reimbursement, and practice-pattern considerations influencing uptake. Across the United States, access is strongly shaped by payer design, specialty prescribing, affordability support, and coordination across care settings.

Actionable Priorities for Leaders in Enzalutamide Tablet Care

Industry leaders should align evidence generation with clinically meaningful outcomes across relevant disease states and treatment sequences, while maintaining clear safety information and responsible communication. Strengthening patient-support services can improve adherence, education, interaction management, and timely toxicity escalation. Access strategies should account for country-specific reimbursement, procurement, and distribution realities rather than relying on a single global model. Partnerships with oncology networks and health systems can support real-world evidence, equitable diagnosis, and care coordination. AI investments should prioritize validated use cases, governance, interoperability, bias monitoring, and measurable improvements in clinical workflow and patient experience.

Research Methodology: Evidence-Led Assessment of the Enzalutamide Tablet Landscape

This executive summary is based on a structured review framework covering regulatory indications, clinical guidelines, peer-reviewed evidence, safety information, treatment pathways, reimbursement considerations, healthcare-system characteristics, and regional access conditions. Findings are synthesized qualitatively across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and across the specified economic, political, and country groupings. Conclusions distinguish established clinical and policy considerations from emerging technology opportunities, with claims limited to evidence-supported themes and without presenting market estimates, shares, or forecasts.

Conclusion: Durable Value Depends on Evidence, Access, and Coordinated Care

The enzalutamide tablet landscape is defined by the convergence of clinical innovation, earlier treatment integration, oral-therapy management, and unequal access across health systems. Sustainable progress will depend on evidence-based patient selection, proactive safety monitoring, reliable medicine access, and coordinated multidisciplinary care. Leaders that combine rigorous clinical development with locally appropriate reimbursement, support services, and responsible digital innovation will be better positioned to improve treatment delivery while addressing variation in patient needs and healthcare capacity.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Enzalutamide Tablets Market, by Therapy Line
7.1. Introduction
7.2. First-Line Therapy
7.3. Second-Line Therapy
7.4. Third-Line Therapy
8. Enzalutamide Tablets Market, by End User
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Specialty Clinics
8.4.1. Oncology Clinics
8.4.2. Urology Clinics
9. Enzalutamide Tablets Market, by Indication
9.1. Introduction
9.2. Metastatic Castration-Resistant Prostate Cancer
9.3. Metastatic Hormone-Sensitive Prostate Cancer
9.4. Non-Metastatic Castration-Resistant Prostate Cancer
10. Enzalutamide Tablets Market, by Distribution Channel
10.1. Introduction
10.2. Online
10.2.1. Manufacturer Websites
10.2.2. eCommerce Platforms
10.3. Offline
11. Enzalutamide Tablets Market, by Dosage Strength
11.1. Introduction
11.2. 120 mg
11.3. 160 mg
11.4. 40 mg
11.5. 80 mg
12. Enzalutamide Tablets Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Enzalutamide Tablets Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Enzalutamide Tablets Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alkem Laboratories Ltd.
16.2. Astellas Pharma Inc.
16.3. Aurobindo Pharma Limited
16.4. Bayer AG
16.5. Cadila Healthcare Limited
16.6. Cipla Limited
16.7. Dr. Reddy's Laboratories Ltd.
16.8. Fresenius Kabi AG
16.9. Glenmark Pharmaceuticals Limited
16.10. Hetero Labs Limited
16.11. Intas Pharmaceuticals Ltd.
16.12. Johnson & Johnson
16.13. Lupin Limited
16.14. Mylan N.V.
16.15. Natco Pharma Limited
16.16. Pfizer Inc.
16.17. Sun Pharmaceutical Industries Ltd.
16.18. Teva Pharmaceutical Industries Ltd.
16.19. Torrent Pharmaceuticals Ltd.
16.20. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Enzalutamide Tablets Market, Years Considered for the Study
FIGURE 2. Global Enzalutamide Tablets Market, Research Design
FIGURE 3. Global Enzalutamide Tablets Market, Research Framework
FIGURE 4. Global Enzalutamide Tablets Market, Data Triangulation
FIGURE 5. Global Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Enzalutamide Tablets Market Size, by Therapy Line, 2025 vs 2032 (%)
FIGURE 7. Global Enzalutamide Tablets Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Enzalutamide Tablets Market Size, by End User, 2025 vs 2032 (%)
FIGURE 9. Global Enzalutamide Tablets Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Enzalutamide Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Enzalutamide Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Enzalutamide Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Enzalutamide Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Enzalutamide Tablets Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 15. Global Enzalutamide Tablets Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Enzalutamide Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Enzalutamide Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Enzalutamide Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Enzalutamide Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Enzalutamide Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Enzalutamide Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Enzalutamide Tablets Market Segmentation & Coverage
TABLE 2. Global Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 4. Global First-Line Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global First-Line Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global First-Line Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Second-Line Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Second-Line Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Second-Line Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Third-Line Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Third-Line Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Third-Line Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 14. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Urology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Urology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Urology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 30. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 40. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Manufacturer Websites Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Manufacturer Websites Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Manufacturer Websites Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global eCommerce Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global eCommerce Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global eCommerce Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 53. Global 120 mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global 120 mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global 120 mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global 160 mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global 160 mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global 160 mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global 40 mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global 40 mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global 40 mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global 80 mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global 80 mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global 80 mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 74. North America Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. North America Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 76. North America Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. North America Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 78. North America Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 79. North America Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. North America Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 81. North America Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 82. Latin America Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Latin America Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 84. Latin America Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Latin America Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 86. Latin America Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. Latin America Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Latin America Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 89. Latin America Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 90. Europe Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Europe Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 92. Europe Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Europe Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 94. Europe Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 95. Europe Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Europe Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 97. Europe Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 98. Middle East Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Middle East Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 100. Middle East Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Middle East Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 102. Middle East Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Middle East Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Middle East Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 105. Middle East Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. Africa Enzalutamide Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Africa Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 108. Africa Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 109. Africa Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 110. Africa Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 111. Africa Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Africa Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 113. Africa Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 114. Global Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. ASEAN Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 117. ASEAN Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. ASEAN Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 119. ASEAN Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. ASEAN Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. ASEAN Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 122. ASEAN Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 123. GCC Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. GCC Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 125. GCC Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. GCC Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 127. GCC Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. GCC Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. GCC Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 130. GCC Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 131. European Union Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. European Union Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 133. European Union Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. European Union Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 135. European Union Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. European Union Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. European Union Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 138. European Union Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 139. BRICS Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. BRICS Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 141. BRICS Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. BRICS Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 143. BRICS Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. BRICS Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. BRICS Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 146. BRICS Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 147. G7 Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. G7 Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 149. G7 Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. G7 Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 151. G7 Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. G7 Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. G7 Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 154. G7 Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 155. NATO Enzalutamide Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. NATO Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 157. NATO Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. NATO Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 159. NATO Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. NATO Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. NATO Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 162. NATO Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 163. Global Enzalutamide Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. United States Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 165. United States Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 166. United States Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. United States Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 168. United States Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. United States Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. United States Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 171. United States Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 172. Canada Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 173. Canada Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 174. Canada Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Canada Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 176. Canada Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. Canada Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Canada Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 179. Canada Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 180. Mexico Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 181. Mexico Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 182. Mexico Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Mexico Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 184. Mexico Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. Mexico Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Mexico Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 187. Mexico Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 188. Brazil Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 189. Brazil Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 190. Brazil Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Brazil Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 192. Brazil Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. Brazil Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Brazil Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 195. Brazil Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 196. United Kingdom Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 197. United Kingdom Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 198. United Kingdom Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. United Kingdom Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 200. United Kingdom Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. United Kingdom Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. United Kingdom Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 203. United Kingdom Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 204. Germany Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 205. Germany Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 206. Germany Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. Germany Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 208. Germany Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 209. Germany Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Germany Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 211. Germany Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 212. France Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 213. France Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 214. France Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. France Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 216. France Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 217. France Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. France Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 219. France Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 220. Russia Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 221. Russia Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 222. Russia Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. Russia Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 224. Russia Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. Russia Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Russia Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 227. Russia Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 228. Italy Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 229. Italy Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 230. Italy Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. Italy Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 232. Italy Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Italy Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Italy Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 235. Italy Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 236. Spain Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 237. Spain Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 238. Spain Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. Spain Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 240. Spain Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 241. Spain Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. Spain Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 243. Spain Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 244. China Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 245. China Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 246. China Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. China Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 248. China Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 249. China Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. China Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 251. China Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 252. India Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 253. India Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 254. India Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 255. India Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 256. India Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. India Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. India Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 259. India Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 260. Japan Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 261. Japan Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 262. Japan Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. Japan Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 264. Japan Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 265. Japan Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Japan Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 267. Japan Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 268. Australia Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 269. Australia Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 270. Australia Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Australia Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 272. Australia Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 273. Australia Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. Australia Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 275. Australia Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 276. South Korea Enzalutamide Tablets Market Size, 2017-2032 (USD Million)
TABLE 277. South Korea Enzalutamide Tablets Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 278. South Korea Enzalutamide Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 279. South Korea Enzalutamide Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 280. South Korea Enzalutamide Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 281. South Korea Enzalutamide Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. South Korea Enzalutamide Tablets Market Size, by Online, 2017-2032 (USD Million)
TABLE 283. South Korea Enzalutamide Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 284. Global Enzalutamide Tablets Market Share, by Key Player, 2025
TABLE 285. Global Enzalutamide Tablets Market, Key Experts

Companies Mentioned

  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Healthcare Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Mylan N.V.
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Enzalutamide Drugs Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Drugs Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Enzalutamide Soft Capsules Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Soft Capsules Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Sotorasib Tablets Market Report 2026 - Product Image

Sotorasib Tablets Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nimesulide Dispersible Tablet Market Report 2026 - Product Image

Nimesulide Dispersible Tablet Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Detachable Tablets - Global Strategic Business Report - Product Image

Detachable Tablets - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.